Teratogenic effects of the anticonvulsant gabapentin in mice

Prakash, L. V. Prabhu, R. Rai, M. M. Pai, S. K. Yadav, S. Madhyastha, R. K. Goel, G. Singh, M. A. Nasar

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Introduction: We aim to study and elucidate the safety profile of the antiepileptic doses of gabapentin during pregnancy, and to evaluate gabapentin-induced murine fetotoxicity at different dose levels. Methods: A total of 60 pregnant mice, divided into 12 groups of five mice each, were exposed to gabapentin in four different doses of 0 (control), 113, 226, or 452 mg/kg body weight per day, at three different gestational stages including early gestation (1-6 days), mid-gestation (7-12 days), and late gestation (13-17 days). The pregnant mice were euthanised on day 18 of gestation, and foetuses were examined for teratogenic manifestations. Their brains were dissected and examined for gross changes, malformations, histological changes, and quantitative protein estimation. Results: Foetal resorptions were observed in all treated groups with gabapentin administration at early gestation (1-6 days), and mid-gestation (7-12 days). On the other hand, growth retardation along with stunting in size of live foetuses were observed in all the mid-gestation (7-12 days), and late gestation (13-17 days) treated groups. Various gross malformations were observed with all the three doses (113, 226, and 452 mg/kg body weight per day) when gabapentin was administered at mid-gestation (7-12 days). The same trends were confirmed by gross and microscopic examination of brains along with quantitative protein estimation. Conclusion: Gabapentin should not be prescribed during pregnancy, as no therapeutic dose of gabapentin is safe during this period as far as the foetal well-being is concerned.

Original languageEnglish
Pages (from-to)47-53
Number of pages7
JournalSingapore Medical Journal
Volume49
Issue number1
Publication statusPublished - 01-2008

Fingerprint

Anticonvulsants
Pregnancy
Fetus
gabapentin
Fetal Resorption
Body Weight
Growth Disorders
Brain
Proteins
Safety

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Prakash, Prabhu, L. V., Rai, R., Pai, M. M., Yadav, S. K., Madhyastha, S., ... Nasar, M. A. (2008). Teratogenic effects of the anticonvulsant gabapentin in mice. Singapore Medical Journal, 49(1), 47-53.
Prakash, ; Prabhu, L. V. ; Rai, R. ; Pai, M. M. ; Yadav, S. K. ; Madhyastha, S. ; Goel, R. K. ; Singh, G. ; Nasar, M. A. / Teratogenic effects of the anticonvulsant gabapentin in mice. In: Singapore Medical Journal. 2008 ; Vol. 49, No. 1. pp. 47-53.
@article{80c46571224548f7af6582fbe8678b59,
title = "Teratogenic effects of the anticonvulsant gabapentin in mice",
abstract = "Introduction: We aim to study and elucidate the safety profile of the antiepileptic doses of gabapentin during pregnancy, and to evaluate gabapentin-induced murine fetotoxicity at different dose levels. Methods: A total of 60 pregnant mice, divided into 12 groups of five mice each, were exposed to gabapentin in four different doses of 0 (control), 113, 226, or 452 mg/kg body weight per day, at three different gestational stages including early gestation (1-6 days), mid-gestation (7-12 days), and late gestation (13-17 days). The pregnant mice were euthanised on day 18 of gestation, and foetuses were examined for teratogenic manifestations. Their brains were dissected and examined for gross changes, malformations, histological changes, and quantitative protein estimation. Results: Foetal resorptions were observed in all treated groups with gabapentin administration at early gestation (1-6 days), and mid-gestation (7-12 days). On the other hand, growth retardation along with stunting in size of live foetuses were observed in all the mid-gestation (7-12 days), and late gestation (13-17 days) treated groups. Various gross malformations were observed with all the three doses (113, 226, and 452 mg/kg body weight per day) when gabapentin was administered at mid-gestation (7-12 days). The same trends were confirmed by gross and microscopic examination of brains along with quantitative protein estimation. Conclusion: Gabapentin should not be prescribed during pregnancy, as no therapeutic dose of gabapentin is safe during this period as far as the foetal well-being is concerned.",
author = "Prakash and Prabhu, {L. V.} and R. Rai and Pai, {M. M.} and Yadav, {S. K.} and S. Madhyastha and Goel, {R. K.} and G. Singh and Nasar, {M. A.}",
year = "2008",
month = "1",
language = "English",
volume = "49",
pages = "47--53",
journal = "Singapore Medical Journal",
issn = "0037-5675",
publisher = "Singapore Medical Association",
number = "1",

}

Prakash, , Prabhu, LV, Rai, R, Pai, MM, Yadav, SK, Madhyastha, S, Goel, RK, Singh, G & Nasar, MA 2008, 'Teratogenic effects of the anticonvulsant gabapentin in mice', Singapore Medical Journal, vol. 49, no. 1, pp. 47-53.

Teratogenic effects of the anticonvulsant gabapentin in mice. / Prakash, ; Prabhu, L. V.; Rai, R.; Pai, M. M.; Yadav, S. K.; Madhyastha, S.; Goel, R. K.; Singh, G.; Nasar, M. A.

In: Singapore Medical Journal, Vol. 49, No. 1, 01.2008, p. 47-53.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Teratogenic effects of the anticonvulsant gabapentin in mice

AU - Prakash,

AU - Prabhu, L. V.

AU - Rai, R.

AU - Pai, M. M.

AU - Yadav, S. K.

AU - Madhyastha, S.

AU - Goel, R. K.

AU - Singh, G.

AU - Nasar, M. A.

PY - 2008/1

Y1 - 2008/1

N2 - Introduction: We aim to study and elucidate the safety profile of the antiepileptic doses of gabapentin during pregnancy, and to evaluate gabapentin-induced murine fetotoxicity at different dose levels. Methods: A total of 60 pregnant mice, divided into 12 groups of five mice each, were exposed to gabapentin in four different doses of 0 (control), 113, 226, or 452 mg/kg body weight per day, at three different gestational stages including early gestation (1-6 days), mid-gestation (7-12 days), and late gestation (13-17 days). The pregnant mice were euthanised on day 18 of gestation, and foetuses were examined for teratogenic manifestations. Their brains were dissected and examined for gross changes, malformations, histological changes, and quantitative protein estimation. Results: Foetal resorptions were observed in all treated groups with gabapentin administration at early gestation (1-6 days), and mid-gestation (7-12 days). On the other hand, growth retardation along with stunting in size of live foetuses were observed in all the mid-gestation (7-12 days), and late gestation (13-17 days) treated groups. Various gross malformations were observed with all the three doses (113, 226, and 452 mg/kg body weight per day) when gabapentin was administered at mid-gestation (7-12 days). The same trends were confirmed by gross and microscopic examination of brains along with quantitative protein estimation. Conclusion: Gabapentin should not be prescribed during pregnancy, as no therapeutic dose of gabapentin is safe during this period as far as the foetal well-being is concerned.

AB - Introduction: We aim to study and elucidate the safety profile of the antiepileptic doses of gabapentin during pregnancy, and to evaluate gabapentin-induced murine fetotoxicity at different dose levels. Methods: A total of 60 pregnant mice, divided into 12 groups of five mice each, were exposed to gabapentin in four different doses of 0 (control), 113, 226, or 452 mg/kg body weight per day, at three different gestational stages including early gestation (1-6 days), mid-gestation (7-12 days), and late gestation (13-17 days). The pregnant mice were euthanised on day 18 of gestation, and foetuses were examined for teratogenic manifestations. Their brains were dissected and examined for gross changes, malformations, histological changes, and quantitative protein estimation. Results: Foetal resorptions were observed in all treated groups with gabapentin administration at early gestation (1-6 days), and mid-gestation (7-12 days). On the other hand, growth retardation along with stunting in size of live foetuses were observed in all the mid-gestation (7-12 days), and late gestation (13-17 days) treated groups. Various gross malformations were observed with all the three doses (113, 226, and 452 mg/kg body weight per day) when gabapentin was administered at mid-gestation (7-12 days). The same trends were confirmed by gross and microscopic examination of brains along with quantitative protein estimation. Conclusion: Gabapentin should not be prescribed during pregnancy, as no therapeutic dose of gabapentin is safe during this period as far as the foetal well-being is concerned.

UR - http://www.scopus.com/inward/record.url?scp=39049124555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049124555&partnerID=8YFLogxK

M3 - Article

C2 - 18204769

AN - SCOPUS:39049124555

VL - 49

SP - 47

EP - 53

JO - Singapore Medical Journal

JF - Singapore Medical Journal

SN - 0037-5675

IS - 1

ER -